Company / Total Assets
Syndax Pharmaceuticals Inc Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$529.7M
FY2025
5-year range
$449.7M / $724.8M
FY2021-FY2025
Trend
-26.9%
vs FY2024
Sector context
#133 of 214
Health Care
What the data says
At $530M, Syndax Pharmaceuticals Inc's total assets ranks #133 of 214 in the Health Care sector. Total Assets has fluctuated over the past 10 years, ranging from $64M in FY2019 to $725M in FY2024.
Based on SEC 10-K filings.
$530M in FY2025 with a 5-year CAGR of +12.0%.
Declined from $613M to $530M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +2.1%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
#133 of 214 in Health CareTop 62% of 214This company $529.7M Sector average $7.5B
▼
-92.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, total assets decreased 26.9% year-over-year.
- Ranks #133 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $529.7M | -26.9% |
| FY2024 | $724.8M | +18.3% |
| FY2023 | $612.9M | +23.3% |
| FY2022 | $497.2M | +10.6% |
| FY2021 | $449.7M | +49.6% |
| FY2020 | $300.6M | +373.2% |
| FY2019 | $63.5M | -24.3% |
| FY2018 | $83.9M | -38.8% |
| FY2017 | $137.2M | +25.8% |
| FY2016 | $109.0M | +21.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026